| Wolf, Martin |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden |
|
|
| Active, not recruiting | 2 | 98 | Europe | Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO® | Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer | Follicular Lymphoma | 09/23 | 05/26 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
LENNON, NCT05384691: Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions |
|
|
| Recruiting | 2 | 213 | Europe | Luspatercept Injection, LUS | University of Leipzig, Celgene Corporation | Myelodysplastic Syndromes, Anemia | 07/26 | 07/27 | | |
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology |
|
|
| Completed | N/A | 499 | Europe | | iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG | Advanced Solid Tumors or Hematologic Malignancies | 06/23 | 06/23 | | |
| Recruiting | N/A | 1100 | Europe | | Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx | Immune Thrombocytopenia | 09/26 | 04/27 | | |
| WESTEEL, Virginie |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
| PLANCHARD, David |
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 587 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin | AstraZeneca | Non-Small Cell Lung Cancer | 04/23 | 06/26 | | |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Active, not recruiting | 2 | 100 | Europe | DS-1062a | Gustave Roussy, Cancer Campus, Grand Paris, Daiichi Sankyo | Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer | 03/25 | 03/28 | | |
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 185 | Europe, Canada, US, RoW | Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608 | GlaxoSmithKline, iTeos Belgium SA | Neoplasms | 07/25 | 07/25 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
| Recruiting | 1/2 | 200 | Europe, Japan, US, RoW | TAS3351 oral administration | Taiho Oncology, Inc. | Non-Small Cell Lung Cancer | 12/27 | 12/27 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Schott, Roland |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 409 | Europe | Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy | Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium, Ministry of Health, France | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 09/28 | 09/31 | | |
| MAZIERES, Julien |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
| Recruiting | 1/2 | 359 | Europe, Canada, Japan, US, RoW | NVL-520 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 10/25 | 10/26 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 250 | Europe, US, RoW | MYTX-011 | Mythic Therapeutics | NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer | 12/25 | 12/27 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Bozorgmehr, Farastuk |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
TRADE-hypo, NCT04351256: Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy |
|
|
| Recruiting | 2 | 88 | Europe | Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic Radiotherapy (TRT) hypofractionated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, AstraZeneca | NSCLC, Stage III | 10/25 | 06/26 | | |
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung |
|
|
| Recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
| Reinmuth, Niels |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
| Active, not recruiting | 2 | 92 | Europe | Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb | Pleural Mesothelioma Malignant | 12/24 | 01/25 | | |
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung |
|
|
| Recruiting | 2 | 67 | Europe | Atezolizumab | Technische Universität Dresden, Roche Pharma AG | Large Cell Neuroendocrine Carcinoma of the Lung | 01/28 | 01/29 | | |
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1050 | Europe, US | Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay | Razor Genomics, Encore Clinical | Non-Small Cell Lung Cancer | 05/27 | 05/27 | | |
| AUDIGIER-VALETTE, Clarisse |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
DEEP-Lung-IV, NCT04994795: Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | N/A | 4000 | Europe, Canada, US, RoW | Predictive models (data collection) | Sophia Genetics SAS | Non-small Cell Lung Cancer Metastatic | 12/24 | 02/25 | | |
| Schutte, Wolfgang |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
